Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence.
Badr NM, McMurray JL, Danial I, Hayward S, Asaad NY, Abd El-Wahed MM, Abdou AG, Serag El-Dien MM, Sharma N, Horimoto Y, Sircar T, Vidya R, Hoar F, Rea D, Jones JL, Stevens A, Spooner D, Merard R, Lewis P, Hunter KJ, Berditchevski F, Shaaban AM. Badr NM, et al. Pathobiology. 2023;90(1):31-43. doi: 10.1159/000524549. Epub 2022 Jun 15. Pathobiology. 2023. PMID: 35705026 Free article.
The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer.
Hayward S, Gachehiladze M, Badr N, Andrijes R, Molostvov G, Paniushkina L, Sopikova B, Slobodová Z, Mgebrishvili G, Sharma N, Horimoto Y, Burg D, Robertson G, Hanby A, Hoar F, Rea D, Eckhardt BL, Ueno NT, Nazarenko I, Long HM, van Laere S, Shaaban AM, Berditchevski F. Hayward S, et al. Among authors: badr n. J Pathol. 2020 May;251(1):63-73. doi: 10.1002/path.5415. Epub 2020 Mar 24. J Pathol. 2020. PMID: 32129471
Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, Quinn CM, Badr N, Murray C, Provenzano E, Callagy G, Martyn C, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Oyama T, Shaaban AM, Ellis I, Lee AHS, Rakha EA. Katayama A, et al. Among authors: badr n. Mod Pathol. 2021 Jul;34(7):1271-1281. doi: 10.1038/s41379-021-00738-5. Epub 2021 Feb 1. Mod Pathol. 2021. PMID: 33526875 Free PMC article.
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
Rakha EA, Miligy IM, Quinn CM, Provenzano E, Shaaban AM, Marchiò C, Toss MS, Gallagy G, Murray C, Walshe J, Katayama A, Eldib K, Badr N, Tanchel B, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Ellis IO, Lee AHS. Rakha EA, et al. Among authors: badr n. Br J Cancer. 2021 May;124(11):1836-1842. doi: 10.1038/s41416-021-01351-8. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762723 Free PMC article.
46 results